There’s Risk, and Then There’s RISK: The Latest Clinical Prognostic Risk Stratification Models in Myelodysplastic Syndromes

Current Hematologic Malignancy Reports - United States
doi 10.1007/s11899-013-0172-3
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Myelodysplastic Syndromes: 2018 Update on Diagnosis, Risk-Stratification and Management

American Journal of Hematology
Hematology
2017English

Drilling Like There’s No Tomorrow: Bankruptcy, Insurance, and Environmental Risk

American Economic Review
EconomicsEconometrics
2019English

Comparison of Risk Stratification Tools in Predicting Outcomes of Patients With Higher-Risk Myelodysplastic Syndromes Treated With Azanucleosides

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2015English

Histopathology in the Diagnosis of High-Risk Myelodysplastic Syndromes

Journal of clinical and experimental hematopathology : JCEH
Medicine
2018English

Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2012English

CD30 Expression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2013English

Where There’s a Will, There’s a Way

Russia in Global Affairs
SociologyInternational RelationsCultural StudiesPolitical ScienceHistory
2019English

Coalesced Multicentric Analysis of 2,351 Patients With Myelodysplastic Syndromes Indicates an Underestimation of Poor-Risk Cytogenetics of Myelodysplastic Syndromes in the International Prognostic Scoring System

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2011English

There’s the Rub

English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy